Issues at a former Catalent plant now owned by Novo Nordisk have derailed another FDA application. Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.
Novo’s troubled Indiana plant claims another victim as FDA rejects Incyte’s lung cancer application
Latest from Blog
Fueling Prevention: The Role of Nutrition in Colorectal Cancer Prevention
The choices we make at the table influence not only how we feel today, but also our long-term health. When it comes to colorectal cancer, diet can play a critical role. Post
Celebrating March as National Nutrition Month
The theme for this year’s National Nutrition Month, “Discover the Power of Nutrition,” highlights how nutrition has the power to help you thrive. Post Views: 1
Personalized Nutrition Market Set to Reach $30.94 Billion by 2030 at 14.4% CAGR | Asia Pacific Emerging as a High-Growth Hub
Delray Beach, FL, March 11, 2026 (GLOBE NEWSWIRE) — According to a research report published by MarketsandMarkets, the global personalized nutrition market is projected to grow from USD 15.79 billion in 2025
FSNWG Analysis and Alert Note: Executive Summary – 53 million people in the Sahel, West and Central Africa are projected to face food and nutrition insecurity in 2026 (March 2026)
Analysis in English on World about Agriculture and Food and Nutrition; published on 11 Mar 2026 by FSNWG Post Views: 1
Abortion bans increase birth rates and demand for nutrition assistance
A study in Economic Inquiry reveals how total abortion bans are reshaping public health systems and safety‐net programs in the United States. Post Views: 0